Hydroxamic Acids

• 

  Subject Areas on Research

  • A multidisciplinary approach to probing enthalpy-entropy compensation and the interfacial mobility model. 
  • A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin. 
  • Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. 
  • Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. 
  • An enthalpic basis of additivity in biphenyl hydroxamic acid ligands for stromelysin-1. 
  • Antidepressant actions of histone deacetylase inhibitors. 
  • Aqueous solution speciation of Fe(III) complexes with dihydroxamate siderophores alcaligin and rhodotorulic acid and synthetic analogues using electrospray ionization mass spectrometry. 
  • Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. 
  • BiPS, a photocleavable, isotopically coded, fluorescent cross-linker for structural proteomics. 
  • Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer. 
  • Bordetella pertussis FbpA binds both unchelated iron and iron siderophore complexes. 
  • CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. 
  • Contemporary Management of Struvite Stones Using Combined Endourologic and Medical Treatment: Predictors of Unfavorable Clinical Outcome. 
  • Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. 
  • Drug design from the cryptic inhibitor envelope. 
  • Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. 
  • Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. 
  • Environmental factors influence the production of enterobactin, salmochelin, aerobactin, and yersiniabactin in Escherichia coli strain Nissle 1917. 
  • Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. 
  • Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. 
  • FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function. 
  • Factors that influence siderophoremediated iron bioavailability: catalysis of interligand iron (III) transfer from ferrioxamine B to EDTA by hydroxamic acids. 
  • Fe(III) coordination properties of a new saccharide-based exocyclic trihydroxamate analogue of ferrichrome. 
  • Fe(III)-complexes of the tripodal trishydroxamate siderophore basidiochrome: potential biological implications. 
  • Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. 
  • High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors. 
  • Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer. 
  • Histone Deacetylase 7 Inhibition in a Murine Model of Gram-Negative Pneumonia-Induced Acute Lung Injury. 
  • Histone acetylation in keratinocytes enables control of the expression of cathelicidin and CD14 by 1,25-dihydroxyvitamin D3. 
  • Histone deacetylase 3 binds to and regulates the GCMa transcription factor. 
  • Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. 
  • Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli. 
  • Inhibition of matrix metalloproteinase activity reverses corneal endothelial-mesenchymal transition. 
  • Inhibition of matrix metalloproteinases enhances in vitro repair of the meniscus. 
  • Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. 
  • Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. 
  • Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. 
  • Kinetics and mechanism of iron(III) dissociation from the dihydroxamate siderophores alcaligin and rhodotorulic acid. 
  • L-selectin shedding does not regulate human neutrophil attachment, rolling, or transmigration across human vascular endothelium in vitro. 
  • Leukonychia related to vorinostat. 
  • Lipid A Has Significance for Optimal Growth of Coxiella burnetii in Macrophage-Like THP-1 Cells and to a Lesser Extent in Axenic Media and Non-phagocytic Cells. 
  • Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors. 
  • Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. 
  • Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis. 
  • Methods for the analysis of histone H3 and H4 acetylation in blood. 
  • Multiple myeloma, version 1.2013. 
  • Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors. 
  • Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. 
  • Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. 
  • Novel therapies for pancreatic adenocarcinoma. 
  • PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. 
  • PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. 
  • Panobinostat for the management of multiple myeloma. 
  • Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. 
  • Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. 
  • Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. 
  • Phosphorus-based SAHA analogues as histone deacetylase inhibitors. 
  • Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. 
  • QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. 
  • Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. 
  • Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism. 
  • Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections. 
  • Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding. 
  • Suberoylanilide hydroxamic acid represses glioma stem-like cells. 
  • Synthesis and biological activity of saccharide based lipophilic siderophore mimetics as potential growth promoters for mycobacteria. 
  • The extracellular release of HMGB1 during apoptotic cell death. 
  • The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. 
  • The kinetics of dimethylhydroxypyridinone interactions with iron(iii) and the catalysis of iron(iii) ligand exchange reactions: implications for bacterial iron transport and combination chelation therapies. 
  • The selection and evaluation of new chelating agents for the treatment of iron overload. 
  • Thermodynamics, kinetics, and mechanism of the stepwise dissociation and formation of Tris(L-lysinehydroxamato)iron(III) in aqueous acid. 
• 

  Keywords of People

  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society